Deltex Medical (GB:DEMG) has released an update.
Deltex Medical Group’s new TrueVue System, acclaimed for improving surgical outcomes and reducing post-operative complications, has been chosen by the NHS Supply Chain as a pre-approved device for UK hospitals. The framework agreement commencing on 8 June 2024 will enable NHS and approved customers to procure TrueVue System for at least 24 months, with the possibility of a 24-month extension. TrueVue is noted for its unique ability to provide real-time measurements of both blood flow and blood pressure during surgery.
For further insights into GB:DEMG stock, check out TipRanks’ Stock Analysis page.
